These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 19707193)
1. Neurological adverse effects caused by cytotoxic and targeted therapies. Schiff D; Wen PY; van den Bent MJ Nat Rev Clin Oncol; 2009 Oct; 6(10):596-603. PubMed ID: 19707193 [TBL] [Abstract][Full Text] [Related]
2. A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity. Kobrinsky B; Joseph SO; Muggia F; Liebes L; Beric A; Malankar A; Ivy P; Hochster H Cancer Chemother Pharmacol; 2013 Nov; 72(5):1073-8. PubMed ID: 24048674 [TBL] [Abstract][Full Text] [Related]
3. Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management. Wolter P; Schöffski P Acta Oncol; 2010; 49(1):13-23. PubMed ID: 19900123 [TBL] [Abstract][Full Text] [Related]
4. Innovations in antineoplastic therapy. Kaplow R Nurs Clin North Am; 2005 Mar; 40(1):77-94. PubMed ID: 15733948 [TBL] [Abstract][Full Text] [Related]
5. Chemotherapeutic agents and the skin: An update. Heidary N; Naik H; Burgin S J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708 [TBL] [Abstract][Full Text] [Related]
6. Bevacizumab + sunitinib: microangiopathic haemolytic anaemia. A serious drug interaction between 2 cancer drugs. Prescrire Int; 2009 Aug; 18(102):165. PubMed ID: 19746526 [No Abstract] [Full Text] [Related]
7. Recent advances of molecular targeted agents: opportunities for imaging. Dancey JE Cancer Biol Ther; 2003; 2(6):601-9. PubMed ID: 14688462 [TBL] [Abstract][Full Text] [Related]
9. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors]. Deslandres M; Sibaud V; Chevreau C; Delord JP Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Girardi F; Franceschi E; Brandes AA Oncologist; 2010; 15(7):683-94. PubMed ID: 20547589 [TBL] [Abstract][Full Text] [Related]
11. [Treatment with antiangiogenic drugs]. Saijo N Nihon Rinsho; 2010 Jun; 68(6):1007-13. PubMed ID: 20535948 [TBL] [Abstract][Full Text] [Related]
12. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278 [TBL] [Abstract][Full Text] [Related]
13. Imatinib-induced interstitial lung disease and sunitinib-associated intra-tumour haemorrhage. Loong HH; Yeo W Hong Kong Med J; 2008 Dec; 14(6):495-8. PubMed ID: 19060352 [TBL] [Abstract][Full Text] [Related]
14. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST. Blay JY Cancer Treat Rev; 2011 Aug; 37(5):373-84. PubMed ID: 21195552 [TBL] [Abstract][Full Text] [Related]
16. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib. George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558 [TBL] [Abstract][Full Text] [Related]
17. Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B. Ceresa C; Avan A; Giovannetti E; Geldof AA; Avan A; Cavaletti G; Peters GJ Anticancer Res; 2014 Jan; 34(1):517-23. PubMed ID: 24403510 [TBL] [Abstract][Full Text] [Related]
18. A phase I trial of bortezomib with temozolomide in patients with advanced melanoma: toxicities, antitumor effects, and modulation of therapeutic targets. Su Y; Amiri KI; Horton LW; Yu Y; Ayers GD; Koehler E; Kelley MC; Puzanov I; Richmond A; Sosman JA Clin Cancer Res; 2010 Jan; 16(1):348-57. PubMed ID: 20028756 [TBL] [Abstract][Full Text] [Related]
19. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817 [TBL] [Abstract][Full Text] [Related]
20. Combinations of targeted therapies take aim at multiple pathways. Goldman B J Natl Cancer Inst; 2003 Nov; 95(22):1656-7. PubMed ID: 14625255 [No Abstract] [Full Text] [Related] [Next] [New Search]